Glucose metabolism is increased in most aggressive tumors and it is commonly evaluated by positron emission tomography-computed tomography (PET-CT) with 18F-fluorodeoxyglucose ([18F]FDG), measuring the Maximum Standardized Uptake Value (SUVmax) for the assessment. Particularly, it is known that breast cancer expresses different glucose metabolism inrelation to estrogen receptor (ER), progesterone receptor (PR), Ki67 score, tumor grading, tumor size, and Human Epidermal Growth Factor Receptor 2 (HER2). We present an interesting case of a woman with two different, synchronous breast cancers characterized by different glucose metabolism, according to literature knowledge.
Keyphrases
- positron emission tomography
- estrogen receptor
- pet ct
- computed tomography
- epidermal growth factor receptor
- pet imaging
- tyrosine kinase
- advanced non small cell lung cancer
- healthcare
- endothelial cells
- systematic review
- magnetic resonance imaging
- neoadjuvant chemotherapy
- rectal cancer
- radiation therapy
- dual energy
- image quality
- contrast enhanced
- locally advanced